The SNM has announcedthe formation of theMolecular Imaging ClinicalTrials Network, a multi-institutionaleffort to establishscientifically sound, efficientways to evaluate proposedclinical applicationsof biomarker imaging.
The SNM has announced the formation of the Molecular Imaging Clinical Trials Network, a multi-institutional effort to establish scientifically sound, efficient ways to evaluate proposed clinical applications of biomarker imaging.
The network will provide investigational new drugs to the pharma industry and to molecular imaging researchers to develop the next generation of diagnostic and therapeutic agents, according to SNM officials. It will also coordinate imaging protocols and equipment calibration for multicenter clinical trials.
Scientific investigation under the program should start in the first quarter of 2009.
Computed Tomography Study Assesses Model for Predicting Recurrence of Non-Small Cell Lung Cancer
January 31st 2025A predictive model for non-small cell lung cancer (NSCLC) recurrence, based on clinical parameters and CT findings, demonstrated an 85.2 percent AUC and 83.3 percent sensitivity rate, according to external validation testing in a new study.